Abivax SA announced the organization of a virtual KOL Investor Event on February 6, 2024. The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD. Along with Abivax?s management, they will be discussing the unmet medical need and current treatment landscape for patients suffering from ulcerative colitis (UC).

The event will also highlight the ongoing and future clinical development plans for obefazimod, Abivax's lead drug candidate, and include a discussion of the mechanism of action, along with the Phase 2b clinical data and Phase 3 trial design for the treatment of adults with moderately to severely active UC. Obefazimod is an oral small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response.